Lung tumourigenesis in a conditional Cul4A transgenic mouse model

Journal of Pathology

Volumn 233, Issue 2, 2014, Pages 113-123

  Yang, Yi Lin ^a   Hung, Ming Szu ^a,b,c,d   Wang, Yang ^a,e   Ni, Jian ^a,f   Mao, Jian Hua ^g   Hsieh, David ^a   Au, Alfred ^a   Kumar, Atul ^a   Quigley, David ^a   Fang, Li Tai ^a   Yeh, Che Chung ^a   Xu, Zhidong ^a   Jablons, David M ^a   You, Liang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f SHANGHAI PULMONARY HOSPITAL   (China)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ad Cre; cell cycle; Cul4A; non small cell lung cancer; transgenic mouse models

Indexed keywords

CISPLATIN; CULLIN4A; PERICENTRIN; PROTEIN P16; PROTEIN P27; REPLICATION LICENSING FACTOR CDT1; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPITHELIUM CELL; EXPERIMENTAL THERAPY; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG; LUNG ADENOCARCINOMA; LUNG CANCER CELL; LUNG TUMOR; LUNG TUMORIGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

AD-CRE; CELL CYCLE; CUL4A; NON-SMALL CELL LUNG CANCER; TRANSGENIC MOUSE MODELS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; CULLIN PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P19; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; NEOPLASM GRADING; PROLIFERATING CELL NUCLEAR ANTIGEN; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84900530236     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4352     Document Type: Article

References (40)

1. Chen LC, Manjeshwar S, Lu Y, et al., The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 1998; 58: 3677-3683.
2. Shinomiya T, Mori T, Ariyama Y, et al., Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer 1999; 24: 337-344.
3. Yasui K, Arii S, Zhao C, et al., TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002; 35: 1476-1484.
4. Abba MC, Fabris VT, Hu Y, et al., Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 2007; 67: 4104-4112.
5. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, et al., Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 2009; 11: R86.
6. Ren S, Xu C, Cui Z, et al., Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) 2012; 90: 1121-1132.
7. Liu L, Lee S, Zhang J, et al., CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol Cell 2009; 34: 451-460.
8. Hung MS, Mao JH, Xu Z, et al., Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med 2011; 15: 350-358.
9. Castillo SD, Angulo B, Suarez-Gauthier A, et al., Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer. J Pathol 2010; 222: 89-98.
10. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al., Oncomine 3.0: genes, pathways, and networks in a collection of 18 000 cancer gene expression profiles. Neoplasia 2007; 9: 166-180.
11. Cerami E, Gao J, Dogrusoz U, et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401-404.
12. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
13. Li T, Hung MS, Wang Y, et al., Transgenic mice for cre-inducible overexpression of the Cul4A gene. Genesis 2011; 49: 134-141.
14. Jackson EL, Willis N, Mercer K, et al., Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
15. DuPage M, Dooley AL, Jacks T,. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009; 4: 1064-1072.
16. Abbas T, Sivaprasad U, Terai K, et al., PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4-Cdt2 ubiquitin ligase complex. Genes Dev 2008; 22: 2496-2506.
17. Kim Y, Starostina NG, Kipreos ET,. The CRL4-Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing. Genes Dev 2008; 22: 2507-2519.
18. Nishitani H, Shiomi Y, Iida H, et al., CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem 2008; 283: 29045-29052.
19. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
20. Loda M, Cukor B, Tam SW, et al., Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-234.
21. Porter PL, Malone KE, Heagerty PJ, et al., Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-225.
22. Chu IM, Hengst L, Slingerland JM,. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267.
23. Philipp-Staheli J, Kim KH, Payne SR, et al., Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 2002; 1: 355-368.
24. Yan Y, Zhang X, Legerski RJ,. Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27. Cell Cycle 2011; 10: 4098-4109.
25. Higa LA, Mihaylov IS, Banks DP, et al., Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 2003; 5: 1008-1015.
26. Nishitani H, Sugimoto N, Roukos V, et al., Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J 2006; 25: 1126-1136.
27. Hu J, McCall CM, Ohta T, et al., Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol 2004; 6: 1003-1009.
28. Delaval B, Doxsey SJ,. Pericentrin in cellular function and disease. J Cell Biol 2010; 188: 181-190.
29. To MD, Quigley DA, Mao JH, et al., Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res 2011; 9: 1339-1345.
30. Garnis C, Lockwood WW, Vucic E, et al., High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006; 118: 1556-1564.
31. Cang Y, Zhang J, Nicholas SA, et al., DDB1 is essential for genomic stability in developing epidermis. Proc Natl Acad Sci USA 2007; 104: 2733-2737.
32. Cang Y, Zhang J, Nicholas SA, et al., Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell 2006; 127: 929-940.
33. Kotake Y, Zeng Y, Xiong Y,. DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res 2009; 69: 1809-1814.
34. Esteller M, Sanchez-Cespedes M, Rosell R, et al., Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.
35. Andujar P, Wang J, Descatha A, et al., p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 2010; 67: 23-30.
36. Martin-Caballero J, Flores JM, Garcia-Palencia P, et al., Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-6238.
37. Soucy TA, Smith PG, Milhollen MA, et al., An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
38. Belani CP, Langer C, Group TAXS,. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 2002; 38 (suppl 4): 13-19.
39. Schiller JH, Harrington D, Belani CP, et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
40. Nawrocki ST, Kelly KR, Smith PG, et al., Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 2013; 19: 3577-3590.